130 related articles for article (PubMed ID: 12354067)
1. Molecular modeling of cytochrome P450 1A1: enzyme-substrate interactions and substrate binding affinities.
Szklarz GD; Paulsen MD
J Biomol Struct Dyn; 2002 Oct; 20(2):155-62. PubMed ID: 12354067
[TBL] [Abstract][Full Text] [Related]
2. Regiospecificity of human cytochrome P450 1A1-mediated oxidations: the role of steric effects.
Ericksen SS; Szklarz GD
J Biomol Struct Dyn; 2005 Dec; 23(3):243-56. PubMed ID: 16218752
[TBL] [Abstract][Full Text] [Related]
3. Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis.
Lewis BC; Mackenzie PI; Miners JO
Arch Biochem Biophys; 2007 Dec; 468(1):58-69. PubMed ID: 17959138
[TBL] [Abstract][Full Text] [Related]
4. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism.
Liu J; Ericksen SS; Sivaneri M; Besspiata D; Fisher CW; Szklarz GD
Arch Biochem Biophys; 2004 Apr; 424(1):33-43. PubMed ID: 15019834
[TBL] [Abstract][Full Text] [Related]
5. Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.
Li W; Tang Y; Liu H; Cheng J; Zhu W; Jiang H
Proteins; 2008 May; 71(2):938-49. PubMed ID: 18004755
[TBL] [Abstract][Full Text] [Related]
6. Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: case of residue 382.
Liu J; Ericksen SS; Besspiata D; Fisher CW; Szklarz GD
Drug Metab Dispos; 2003 Apr; 31(4):412-20. PubMed ID: 12642467
[TBL] [Abstract][Full Text] [Related]
7. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
8. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
9. Application of 3-dimensional homology modeling of cytochrome P450 2B1 for interpretation of site-directed mutagenesis results.
Szklarz GD; Ornstein RL; Halpert JR
J Biomol Struct Dyn; 1994 Aug; 12(1):061-78. PubMed ID: 7848559
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Ala62Pro polymorphic variant of human cytochrome P450 1A1 using recombinant protein expression.
Lee SH; Kang S; Dong MS; Park JD; Park J; Rhee S; Ryu DY
Toxicol Appl Pharmacol; 2015 Jun; 285(3):159-69. PubMed ID: 25902338
[TBL] [Abstract][Full Text] [Related]
12. Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1A1: a CO flash photolysis study.
Koley AP; Buters JT; Robinson RC; Markowitz A; Friedman FK
Arch Biochem Biophys; 1996 Dec; 336(2):261-7. PubMed ID: 8954573
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
14. Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants.
Tu Y; Deshmukh R; Sivaneri M; Szklarz GD
Drug Metab Dispos; 2008 Nov; 36(11):2371-80. PubMed ID: 18703643
[TBL] [Abstract][Full Text] [Related]
15. Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions.
Sheng C; Zhang W; Zhang M; Song Y; Ji H; Zhu J; Yao J; Yu J; Yang S; Zhou Y; Zhu J; Lu J
J Biomol Struct Dyn; 2004 Aug; 22(1):91-9. PubMed ID: 15214809
[TBL] [Abstract][Full Text] [Related]
16. Docking and QSAR comparative studies of polycyclic aromatic hydrocarbons and other procarcinogen interactions with cytochromes P450 1A1 and 1B1.
Gonzalez J; Marchand-Geneste N; Giraudel JL; Shimada T
SAR QSAR Environ Res; 2012 Jan; 23(1-2):87-109. PubMed ID: 22150106
[TBL] [Abstract][Full Text] [Related]
17. Construction of a human cytochrome P450 1A1: rat NADPH-cytochrome P450 reductase fusion protein cDNA and expression in Escherichia coli, purification, and catalytic properties of the enzyme in bacterial cells and after purification.
Chun YJ; Shimada T; Guengerich FP
Arch Biochem Biophys; 1996 Jun; 330(1):48-58. PubMed ID: 8651703
[TBL] [Abstract][Full Text] [Related]
18. Role of LYS271 and LYS279 residues in the interaction of cytochrome P4501A1 with NADPH-cytochrome P450 reductase.
Cvrk T; Strobel HW
Arch Biochem Biophys; 2001 Jan; 385(2):290-300. PubMed ID: 11368010
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling of cytochrome P450 2B1: mode of membrane insertion and substrate specificity.
Dai R; Pincus MR; Friedman FK
J Protein Chem; 1998 Feb; 17(2):121-9. PubMed ID: 9535274
[TBL] [Abstract][Full Text] [Related]
20. Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme.
Sridhar J; Liu J; Komati R; Schroeder R; Jiang Q; Tram P; Riley K; Foroozesh M
Drug Metab Lett; 2017; 10(4):270-277. PubMed ID: 28000546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
